Abiraterone and increased survival in metastatic prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Androstenols
  • Antineoplastic Combined Chemotherapy Protocols
  • Prostatic Neoplasms
  • Steroid 17-alpha-Hydroxylase

abstract

  • The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).

authors

publication date

  • May 26, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3471149

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1014618

PubMed ID

  • 21612468

Additional Document Info

start page

  • 1995

end page

  • 2005

volume

  • 364

number

  • 21